Curon Biopharmaceutical Company Profile

Overview

Curon Biopharmaceutical is a developer of drugs designed for immuno-oncology therapies. The company's drugs consist of multiple class-leading cancer immunotherapeutic agents that aim to address the shortcomings of current cancer treatment paradigms, enabling physicians to provide advanced cancer immunotherapies to their patients.

• ​Year Founded: 2018
• ​Status: Private
• ​Latest Deal Type: Series A
• ​Latest Deal Amount: $150M
• ​Investors: 4

Contact Information

• ​

  Website: www.curonbiopharma.com

• ​

  Corporate Office:

  • ​Room 702, Building B
  • ​No.666 Haike Road, Pudong New Area
  • ​Shanghai, China
• ​

  Ownership Status: Privately Held (backing)

• ​

  Financing Status: Venture Capital-Backed

• ​

  Primary Industry: Drug Discovery

• ​

  Other Industries: Biotechnology

Valuation & Funding

• ​Deal Type: Early Stage VC (Series A)
• ​Date: 30-Jul-2018
• ​Amount: $150M
• ​Status: Completed
• ​Stage: Pre-Clinical Trials

Investors

• ​120 Capital (Venture Capital, Minority)
• ​6 Dimensions Capital (Venture Capital, Minority)
• ​Boyu Capital (Asset Manager, Minority)
• ​Temasek Holdings (Sovereign Wealth Fund, Minority)

FAQs

When was Curon Biopharmaceutical founded?

Curon Biopharmaceutical was founded in 2018.

Where is Curon Biopharmaceutical headquartered?

Curon Biopharmaceutical is headquartered in Shanghai, China.

What industry is Curon Biopharmaceutical in?

Curon Biopharmaceutical’s primary industry is Drug Discovery.

Is Curon Biopharmaceutical a private or public company?

Curon Biopharmaceutical is a private company.

What is Curon Biopharmaceutical’s current revenue?

The current revenue for Curon Biopharmaceutical is not disclosed.

How much funding has Curon Biopharmaceutical raised over time?

Curon Biopharmaceutical has raised $150M.

Who are Curon Biopharmaceutical’s investors?

120 Capital, 6 Dimensions Capital, Boyu Capital, and Temasek Holdings have invested in Curon Biopharmaceutical.